Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate (Q38473460)

3 September 2017

1 reference

title

Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate (English)

1 reference

3 September 2017

Michael E Farhangian

1

1 reference

3 September 2017

Steven R Feldman

series ordinal

2

1 reference

3 September 2017

publication date

12 May 2015

1 reference

American Journal of Clinical Dermatology

3 September 2017

published in

1 reference

3 September 2017

volume

16

1 reference

3 September 2017

issue

4

1 reference

3 September 2017

page(s)

285-294

1 reference

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Immunogenicity of biotherapy used in psoriasis: the science behind the scenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Immunogenicity in biologic therapy: implications for dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Immunogenicity of anti-TNFα therapy in psoriasis: a clinical issue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Antidrug antibodies in psoriasis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Secukinumab in plaque psoriasis--results of two phase 3 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Radioimmunoassay, enzyme and non-enzyme-based immunoassays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Impact of anti-drug antibodies in preclinical pharmacokinetic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Low-dose methotrexate - a therapeutical kick in TNF-alpha antagonist treatment for recalcitrant psoriasis vulgaris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-015-0131-Y

10.1007/S40257-015-0131-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1043295710

0 references

1 reference